Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: A descriptive analysis of the Eurobact II study
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessAttribution 4.0 Internationalhttps://creativecommons.org/licenses/by/4.0/Tarih
2022Yazar
Buetti, NiccolòTabah, Alexis
Loiodice, Ambre
Ruckly, Stéphane
Aslan, Abdullah Tarık
Montrucchio, Giorgia
Cortegiani, Andrea
Saltoğlu, Neşe
Kayaaslan, Bircan
Aksoy, Firdevs
Murat, Akova
Akdoğan, Özlem
Saraçoğlu, Kemal Tolga
Erdoğan, Cem
Leone, Marc
Ferrer, Ricard
Paiva, José-Artur
Hayashi, Yoshiro
Ramanan, Mahesh
Conway Morris, Andrew
Barbier, François
Timsit, Jean-François
Lipman, Jeffrey
Litton, Edward
Palermo, Anna Maria
Yap, Timothy
Eroğlu, Ege
Hosokawa, Koji
Yoshida, Hideki
Fujitani, Shigeki
Zand, Farid
Mahmoodpoor, Ata
Tabatabaei, Seyed Mohammad Nasirodin
Elrabi, Omar
Almekhlafi, Ghaleb A.
Vidal, Gabriela
Aparicio, Marta
Alonzo, Irene
Namendys-Silva, Silvio A.
Hermosillo, Mariana
Castillo, Roberto Alejandro
De Bus, Liesbet
De Waele, Jan
Hollevoet, Isabelle
De Schryver, Nicolas
Serck, Nicolas
Kovacevic, Pedja
Zlojutro, Biljana
Ruppe, Etienne
Montravers, Philippe
Dulac, Thierry
Castanera, Jérémy
Massri, Alexandre
Guesdon, Charlotte
Garcon, Pierre
Duprey, Matthieu
Philippart, François
Tran, Marc
Bruel, Cédric
Kalfon, Pierre
Üst veri
Tüm öğe kaydını gösterKünye
Buetti, N., Tabah, A., Loiodice, A., Ruckly, S., Aslan, A. T., Montrucchio, G. ... Kalfon, P. (2022). Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: A descriptive analysis of the Eurobact II study. Critical Care, 26(1). https://doi.org/10.1186/s13054-022-04166-yÖzet
Background: The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods: We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients’ characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results: A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p < 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49–2.45). Conclusions: We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
Critical CareCilt
26Sayı
1Koleksiyonlar
- Makale Koleksiyonu [3661]
- PubMed İndeksli Yayınlar Koleksiyonu [4065]
- Scopus İndeksli Yayınlar Koleksiyonu [6309]
- WoS İndeksli Yayınlar Koleksiyonu [6448]